SCHEMBL20522653

SCHEMBL20522653

CCOC(=O)C1CCN(c2c(C3CCN(C(=O)OC(C)(C)C)CC3)ccc(OC)c2F)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.48
ALDH1A1 P00352 5/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
ATM Q13315 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.45
GAA P10253 2/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PDE4B Q07343 3/20 0.44
PDE4A P27815 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
STS P08842 1/20 0.43
JAK2 O60674 1/20 0.42
JAK3 P52333 1/20 0.42
PTK2 Q05397 1/20 0.42
KDM4E B2RXH2 2/20 0.42
PKM P14618 1/20 0.42
HTT P42858 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20522566 0.88 ALDH1A1 (0.52) HPGDALDH1A1KMT2AMEN1ATM
SCHEMBL20522607 0.84 HPGD (0.48) HPGDALDH1A1KMT2AMEN1ATM
SCHEMBL25330636 0.81 LGMN (0.53) ALDH1A1KMT2AMEN1POLBSMN1; SMN2
SCHEMBL20522647 0.81 ALDH1A1 (0.53) HPGDALDH1A1KMT2AMEN1ATM
SCHEMBL22712801 0.80 HPGD (0.45) HPGDALDH1A1KMT2AMEN1ATM
SCHEMBL22712792 0.79 HPGD (0.56) HPGDALDH1A1KMT2AMEN1ATM
SCHEMBL20522545 0.79 HPGD (0.56) HPGDALDH1A1KMT2AMEN1ATM
SCHEMBL19078350 0.78 STS (0.46) ALDH1A1KMT2AMEN1POLBSMN1; SMN2
SCHEMBL17305269 0.78 NPSR1 (0.52) ALDH1A1KMT2AMEN1ATMGAA
SCHEMBL19078363 0.76 ALDH1A1 (0.47) HPGDALDH1A1KMT2AMEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10968231-B2 Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders SCOHIA PHARMA, INC. (JP) 2021-04-06 US disclosed
US-20200377509-A1 SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-03 US disclosed
EP-3601260-A1 SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS Takeda Pharmaceutical Company Limited (JP) 2020-02-05 EP disclosed
CN-110678458-A Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders 武田药品工业株式会社 2020-01-10 CN disclosed
WO-2018182050-A1 SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10968231-B2 Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders GLP1R, GPR119, GPR65 HPGD 1744/4885ALDH1A1 1160/4885KMT2A 2240/4885
US-20200377509-A1 SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS GLP1R, GPR119, GPR65 HPGD 1744/4885ALDH1A1 1160/4885KMT2A 2240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.